×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ACIU – ac immune sa (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ACIU
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/10
07:07 am
aciu
AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome [Yahoo! Finance]
Low
Report
AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome [Yahoo! Finance]
12/10
07:00 am
aciu
AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome
Low
Report
AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome
11/26
05:34 pm
aciu
Down's Syndrome Market to Exhibit Growth at a CAGR of 3.81% by 2034 | DelveInsight [Yahoo! Finance]
Low
Report
Down's Syndrome Market to Exhibit Growth at a CAGR of 3.81% by 2034 | DelveInsight [Yahoo! Finance]
11/15
12:35 pm
aciu
AC Immune's stock jumps after Parkinson's therapy shows signs of benefit [Yahoo! Finance]
Medium
Report
AC Immune's stock jumps after Parkinson's therapy shows signs of benefit [Yahoo! Finance]
11/15
08:04 am
aciu
AC Immune SA (NASDAQ: ACIU) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Medium
Report
AC Immune SA (NASDAQ: ACIU) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
11/14
02:54 pm
aciu
GSK Raises Prospects For Withdrawn Blood Cancer Drug Blenrep To Return To US Market - Here's Why [Yahoo! Finance]
Medium
Report
GSK Raises Prospects For Withdrawn Blood Cancer Drug Blenrep To Return To US Market - Here's Why [Yahoo! Finance]
11/14
07:09 am
aciu
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease [Yahoo! Finance]
Medium
Report
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease [Yahoo! Finance]
11/14
07:00 am
aciu
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
Medium
Report
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
Date
Time
Symbol
Headline
Impact
12/18
05:17 pm
aciu
Form 6-K AC Immune SA For: Dec 18
Medium
Report
Form 6-K AC Immune SA For: Dec 18
12/13
05:15 pm
aciu
Form SC 13G/A AC Immune SA Filed by: AFFIRIS AG in Liqu
Low
Report
Form SC 13G/A AC Immune SA Filed by: AFFIRIS AG in Liqu
12/10
08:24 am
aciu
Form 6-K AC Immune SA For: Dec 10
Low
Report
Form 6-K AC Immune SA For: Dec 10
11/14
04:36 pm
aciu
Form SC 13G/A AC Immune SA Filed by: BIOTECHNOLOGY VALUE FUND L P
Medium
Report
Form SC 13G/A AC Immune SA Filed by: BIOTECHNOLOGY VALUE FUND L P
11/14
07:00 am
aciu
Form 6-K AC Immune SA For: Nov 14
Medium
Report
Form 6-K AC Immune SA For: Nov 14
11/5
07:16 am
aciu
Form 6-K AC Immune SA For: Nov 05
High
Report
Form 6-K AC Immune SA For: Nov 05
9/27
04:27 pm
aciu
Form 144 AC Immune SA Filed by: Pfeifer Andrea
Low
Report
Form 144 AC Immune SA Filed by: Pfeifer Andrea
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
11/13
AC Immune Q3 2019 Financial Results and Business Update
16.6%
3/30 Form 20-F AC Immune SA For: Dec 31 15.1%
3/23 Form 6-K AC Immune SA For: Mar 23 14.5%
6/11 AC Immune SA (NASDAQ: ACIU) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 11.2%
3/25 AC Immune SA (NASDAQ: ACIU) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. 9.4%
10/21 Massachusetts General Hospital First to Enroll Adults with Down Syndrome in New Nation-Wide Research Study Supported by LuMind IDSC Foundation 8.6%
4/2 AC Immune Presents the Latest Preclinical Data on Novel Drug Targets for Neurodegenerative Diseases 6.8%
11/19 AC Immune SA (NASDAQ: ACIU) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 5.8%
7/17 AC Immune Initiates Phase 1 Study of ACI-3024 Small Molecule Tau Morphomer™, an Investigational Treatment for Alzheimer’s Disease 5.6%
11/20 AC Immune SA (NASDAQ: ACIU) was upgraded by analysts at TheStreet from a "d" rating to a "c" rating. 4.7%
3/30 Form 20-F AC Immune SA For: Dec 31 15.1%
3/23 Form 6-K AC Immune SA For: Mar 23 14.5%
6/11 AC Immune SA (NASDAQ: ACIU) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 11.2%
3/25 AC Immune SA (NASDAQ: ACIU) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. 9.4%
10/21 Massachusetts General Hospital First to Enroll Adults with Down Syndrome in New Nation-Wide Research Study Supported by LuMind IDSC Foundation 8.6%
4/2 AC Immune Presents the Latest Preclinical Data on Novel Drug Targets for Neurodegenerative Diseases 6.8%
11/19 AC Immune SA (NASDAQ: ACIU) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 5.8%
7/17 AC Immune Initiates Phase 1 Study of ACI-3024 Small Molecule Tau Morphomer™, an Investigational Treatment for Alzheimer’s Disease 5.6%
11/20 AC Immune SA (NASDAQ: ACIU) was upgraded by analysts at TheStreet from a "d" rating to a "c" rating. 4.7%
TOP News Decliners
3/26
AC Immune SA (NASDAQ: ACIU) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating.
-30.1%
8/14 Form 6-K AC Immune SA For: Aug 14 -16.8%
3/14 AC Immune SA (NASDAQ: ACIU) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -9.0%
2/24 AC Immune SA (NASDAQ: ACIU) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.4%
4/27 AC Immune SA (NASDAQ: ACIU) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $8.75 price target on the stock. -7.0%
9/26 AC Immune SA (NASDAQ: ACIU) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -6.6%
6/28 Form 6-K AC Immune SA For: Jun 28 -6.1%
3/5 AC Immune SA (NASDAQ: ACIU) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $8.00 price target on the stock. -5.2%
8/12 AC Immune Announces Research Collaboration with University of Pennsylvania Focusing on Pathogenic Protein TDP-43 in Neurodegenerative Diseases -4.0%
2/10 AC Immune SA (NASDAQ: ACIU) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $11.00 price target on the stock. -3.8%
8/14 Form 6-K AC Immune SA For: Aug 14 -16.8%
3/14 AC Immune SA (NASDAQ: ACIU) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -9.0%
2/24 AC Immune SA (NASDAQ: ACIU) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.4%
4/27 AC Immune SA (NASDAQ: ACIU) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $8.75 price target on the stock. -7.0%
9/26 AC Immune SA (NASDAQ: ACIU) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -6.6%
6/28 Form 6-K AC Immune SA For: Jun 28 -6.1%
3/5 AC Immune SA (NASDAQ: ACIU) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $8.00 price target on the stock. -5.2%
8/12 AC Immune Announces Research Collaboration with University of Pennsylvania Focusing on Pathogenic Protein TDP-43 in Neurodegenerative Diseases -4.0%
2/10 AC Immune SA (NASDAQ: ACIU) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $11.00 price target on the stock. -3.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: